Completed PHASE3 INTERVENTIONAL 2-arm NCT03047954

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Sponsor: Vifor Pharma

Conditions Atopic Dermatitis

Interventions Broncho-Vaxom Placebo - Cap

Updated 7 times since 2017 Last updated: Feb 7, 2017 Started: Jul 31, 2003 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03047954, this PHASE3 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Vifor Pharma, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vifor Pharma

Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.